Drugs / Teverelix
Teverelix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03781947 | Nov 2018 → Mar 2020 | — | Antev Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07457164 | Jul 2026 → Sep 2027 expected | prostate cancer | Antev Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teverelix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07457164 ↗ |
| Known as | Antarelix | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103945 ↗ |
| Known as | D-23234 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103945 ↗ |
| Known as | EP-24332 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103945 ↗ |
| Action | Inhibit | “a gonadotrophin releasing hormone antagonist” NCT03781947 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2103945 ↗ |
| Route | Intramuscular | “via subcutaneous or intramuscular route of administration” NCT03781947 ↗ |
| Route | Subcutaneous | “via subcutaneous or intramuscular route of administration” NCT03781947 ↗ |